A5004143697- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- Monoclonal and Polyclonal Antibodies Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Influenza Virus Research Studies
- Advanced Biosensing Techniques and Applications
- Glycosylation and Glycoproteins Research
- Biosensors and Analytical Detection
- Bacillus and Francisella bacterial research
- Intramuscular injections and effects
- SARS-CoV-2 detection and testing
- Vaccine Coverage and Hesitancy
- Long-Term Effects of COVID-19
- Medical Imaging Techniques and Applications
- Respiratory viral infections research
- Lanthanide and Transition Metal Complexes
- Bacterial Infections and Vaccines
- Galectins and Cancer Biology
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Radiopharmaceutical Chemistry and Applications
- Dermatological and COVID-19 studies
Siriraj Hospital
2012-2025
Mahidol University
2012-2025
University of Oxford
2020
Centre for Human Genetics
2020
National Science and Technology Development Agency
2015
National Nanotechnology Center
2015
The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve protection delta omicron variants.A total 224 individuals who completed 2-dose CoronaVac for 6 months were included. We studied reactogenicity immunogenicity after a with (BBIBP), viral vector...
Abstract There are no licensed therapeutics or vaccines available against Zika virus (ZIKV) to counteract its potential for congenital disease. Antibody-based countermeasures targeting the ZIKV envelope protein have been hampered by concerns cross-reactive responses that induce antibody-dependent enhancement (ADE) of heterologous flavivirus infection. Nonstructural 1 (NS1) is a membrane-associated and secreted glycoprotein functions in replication immune evasion but absent from virion....
The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune evasion even in individuals with complete vaccination, because it harbors mutations. Here we examine the capability of booster vaccination following CoronaVac/AZD1222 prime to induce neutralizing antibodies (NAbs) against (BA.1 BA.2) T-cell responses. A total 167 participants primed heterologous for 4-5 months were enrolled, receive AZD1222, BNT162b2, or mRNA-1273 as a third dose. Reactogenicity was...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning immunity in vaccinated individuals is resulting increased numbers SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses neutralizing activities against variants, patients with COVID-19 who had been fully CoronaVac (
The SARS-CoV-2 Omicron variant presents numerous mutations potentially able to evade neutralizing antibodies (NAbs) elicited by COVID-19 vaccines. Therefore, this study aimed provide evidence on a heterologous booster strategy overcome the waning immunity against variants.
This study examined the neutralizing activity and receptor-binding domain (RBD) antibody levels against wild-type omicron BA.1 BA.2 variants in individuals who received three doses of COVID-19 vaccination. The relationship between anti-RBD IgG live virus titers was examined. In total, 310 sera samples from after booster vaccination (third-dose) were tested for specific SARS-CoV-2 RBD surrogate neutralization test (sVNT). assay performed using foci-reduction (FRNT50). strongly correlated with...
Numerous studies have largely focused on short-term immunogenicity in recovered individuals post mRNA vaccination. However, understanding the long-term durability, particularly inactivated and adenoviral vectored vaccines, remains limited. We evaluated antibody responses, omicron variant neutralization, IFN-γ responses 119 previously infected vaccinated with CoronaVac or ChAdOx1 up to six months post-vaccination. Both vaccines elicited robust immune individuals, surpassing those who were...
Abstract Background The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve protection delta omicron variants. Methods A total 224 individuals who completed two-dose CoronaVac for six months were included. We studied reactogenicity immunogenicity following...
To assess the binding antibody response and strength of neutralization against Omicron BA.5 in serum samples from children with different antigen exposures (infection/vaccination) hybrid immunity.This study recruited aged 5-7 years. All were tested for anti-nucleocapsid immunoglobulin (Ig)G, anti-receptor domain (RBD) IgG, total anti-RBD Ig. Neutralizing antibodies (nAbs) determined using a focus reduction test.A 196 unvaccinated infection (n = 57), vaccination alone 71), immunity 68). Our...
Abstract This study examined the neutralizing activity and receptor binding domain (RBD) antibody levels against wild-type omicron BA.1 BA.2 variants in individuals who received three doses of COVID-19 vaccination. The relationship between SARS-CoV-2 RBD live virus titers was examined. In total, 310 sera samples from after booster vaccination (third dose) were tested for specific IgG surrogate neutralization test (sVNT). assay performed using foci-reduction (FRNT50). anti-RBD strongly...
Epithelial cell adhesion molecule (EpCAM) is a promising biomarker for squamous carcinoma (SCC) of the uterine cervix, because it over-expressed in various cancers epithelial origin. However, EpCAM expression reported previous immunohistochemistry (IHC) studies was inconsistent. We hypothesize that membrane-distal part may be lost during tissue preparation, leaving only membrane-proximal available antibody binding and IHC staining. Two new anti-EpCAM MAbs to (WC-2) (WC-1) were generated...
Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning immunity in vaccinated individuals is resulting increased numbers SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses neutralizing activities against patients with COVID-19 who had been fully CoronaVac ( n = 78), but not contracted 170), received AZD1222 as a third vaccination 210). Breakthrough infection was generally detected approximately 88...
There is a limited supply of COVID-19 vaccines, with less than 20% eligible populations in low-income countries having received one dose. Intradermal delivery fractional dose vaccines way to improve global vaccine access, but no studies have reported data on intradermal primary series vaccination. We conducted pilot study examine the safety and immunogenicity three regimens - heterologous regimen CoronaVac ChAdOx1 (CoronaVac-ChAdOx1), homologous (ChAdOx1-ChAdOx1), BNT162b2...
Single-chain variable antibody fragments (scFvs) are attractive candidates for targeted immunotherapy in several human diseases. In this study, a concise humanization strategy combined with an optimized production method humanizing scFvs was successfully employed. Two clones, one directed against the hemagglutinin of H5N1 influenza virus, other EpCAM, cancer biomarker, were used to demonstrate validity method. Heavy chain (VH) and light (VL) regions immunoglobulin genes from mouse hybridoma...
This cohort study, conducted between July and August 2023, evaluated the adverse events (AEs) immune response to a bivalent mRNA-1273.222 (containing sequences of original Wuhan-H1 strain Omicron BA.4/5 variant) booster vaccine in 122 participants. The study included individuals with diverse vaccination histories, their responses were assessed based on anti-receptor binding domain (RBD) IgG levels neutralizing antibodies against wild-type, BA.5, XBB.1.16 variants. Following administration...
Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence vaccine-induced immunity against new Omicron subvariants are still limited. Therefore, our study aimed determine serological immune response COVID-19 after CoronaVac-priming.
Abstract Background The coronavirus 2019 omicron variant has surged rapidly and raises concerns about immune evasion because it harbors mutations even in individuals with complete vaccination. Here, we examine the capability of booster vaccination to induce neutralizing antibodies (NAbs) against (BA.1 BA.2) T-cell responses. Methods A total 167 participants primed heterologous CoronaVac/AZD1222 were enrolled receive AZD1222, BNT162b2, or mRNA-1273 as a dose. Reactogenicity was recorded....
To compare the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine regimen one or two doses of inactivated followed by an in healthy children 5 11 years age, a prospective cohort study was performed at King Chulalongkorn Memorial Hospital Thailand March to June 2022. Healthy age were enrolled received (BNT162b2) (CoronaVac) BNT162b2 regimen. In addition, who BBIBP-CorV 1 3 months prior receive heterologous as third dose (booster). Reactogenicity assessed self-reported...